Developer docs
API playgroundTry for free, no card

Search company profiles

Diagnexia

Full company profile

uuid0004sq7

Namestring
Diagnexia
Legal namestring
Diagnexia UK Limited
Websiteurl
diagnexia.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Diagnexia is a UK-headquartered digital pathology services company operating a cloud-based platform that connects hospital laboratories to a global network of GMC-registered subspecialty pathologists for primary diagnostic reporting (advertised 3–5 day turnaround, with live wait times showing 1.5 days) and secondary consultations (7–10 day turnaround, 4 days live). The company was founded in 2021, with corporate headquarters in Dublin, Ireland and UK operations centred on CQC-registered accessioning facilities in Exeter (digital accessioning) and Oxford (histology and digital accessioning, UKAS ISO 15189:2022 accredited as of November 2025); additional accessioning centres operate in Naperville, Illinois (US) and Toronto, Ontario (Canada), with primary reporting currently available in the UK and Canada.

The core product is the Diagnexia Hub cloud portal, which handles case onboarding, monitoring, and management with integrated synoptic reporting templates that export into customer laboratory information systems (LIS). Supporting offerings include Scanning Services (client-supplied or Diagnexia-operated scanners at its accessioning centres), Analytix (a sub-brand targeting translational research and clinical trials), External Quality Assurance services aligned to NEQAS schemes, and educational programmes including the Diagnexia Dialogues podcast, an annual Histopathology Symposium, and a Computational Pathology Fundamentals course. The platform also integrates an AI multimodal prostate cancer risk stratification tool through a strategic partnership with Artera.

Diagnexia monetizes per-case pathology reporting fees on a quote-based, multi-year subscription model. Its go-to-market is enterprise sales to NHS hospitals, with distribution via The Countess of Chester Hospital National Framework Agreement for Telepathology, Telepathology and Telemedicine Services — a procurement vehicle that gives any NHS hospital in England transparent, pre-cleared access — supplemented by direct contracts with named NHS Trusts (Derriford Hospital, Bedfordshire Hospitals NHS Foundation Trust, East Sussex Healthcare NHS Trust) and international healthcare institutions in Canada and beyond. The company reports no disclosed revenue or institutional venture funding; the only documented capital inflow is an approximately £50,000 grant from Heart of the South West LEP (via the European Regional Development Fund) in August 2023 to purchase a digital pathology scanner.

Short descriptiontext

Diagnexia is a cloud-based digital pathology services company that connects hospital laboratories to a global network of GMC-registered subspecialty pathologists for primary diagnostic reporting, secondary consultations, scanning, and clinical-trial support, primarily serving NHS hospitals via a national framework agreement and select international institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersExeter, United Kingdom
HQ citystring
Exeter
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital pathology services, telepathology reporting, clinical trial pathology, pathology quality assurance, subspecialty pathologist network
Industry4 codes
PRIMARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLALALAG
Diagnostic/Lab & Imaging Referral Marketplaces
Healthcare & Life Sciences/Telehealth Platforms/Telehealth Marketplace & Referral Platforms
SECONDARYHLACAMAJ
Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAFAMAA
Anatomic Pathology (Histopathology & Cytopathology)
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Digital Pathology Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Digital Pathology Reporting Services
TypeSubscription Recurring
Description

Provides primary diagnostic reporting (3-5 day turnaround) and secondary consultation services (7-10 day turnaround) for NHS hospitals and healthcare institutions. Revenue generated through service fees for pathology reporting, with transparent pricing for NHS Framework access.

diagnexia.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Primary Diagnostic Reporting
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Quote-based pricing for NHS hospitals through framework agreement. Turnaround time of 3-5 days for primary diagnostic reports.

diagnexia.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Diagnexia operates a cloud-based digital pathology platform that connects laboratories to a global network of GMC-registered subspecialty pathologists, delivering primary diagnostic reporting and secondary consultation reports for NHS hospitals and healthcare institutions. The company runs UKAS-accredited histology and digital accessioning centres in the UK and provides scanning services, clinical trial pathology support, and external quality assurance services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 3-5 day turnaround for primary diagnostic reports
+3 more records
Product overview1 text field

Diagnexia is a cloud-based digital pathology platform that functions as a 'global digital pathology department,' connecting laboratories worldwide to an international network of subspecialty pathologists. The core product is the Diagnexia Hub platform, which enables primary diagnostic reporting (3-5 day turnaround) and secondary consultation services (7-10 day turnaround). Supporting services include Scanning Services (with two workflow options: client scanner or Diagnexia scanning), Analytix for clinical trials, and External Quality Assurance services. The company also provides educational offerings including the Diagnexia Dialogues podcast and annual Histopathology Symposium events.

Product and service4 records
1Digital Pathology Reporting Services
CategoryDiagnostic Pathology Reporting
Description

Cloud-based delivery of primary diagnostic reports (3-5 day turnaround) and secondary consultation reports (7-10 day turnaround) from a global network of subspecialty pathologists, primarily for NHS hospitals and international healthcare institutions.

2Scanning Services
CategoryLaboratory Scanning Services
Description

Digital pathology slide scanning services with two workflow options: clients use their own scanners or mail slides to Diagnexia's UK or US accessioning centres for digitization and end-to-end specimen tracking.

3Analytix (Clinical Trials Pathology)
CategoryClinical Trial Pathology Services
Description

Digital pathology services designed for translational research and clinical trials, supporting biopharma sponsors with pathology analysis for drug development studies.

4External Quality Assurance (EQA) Services
CategoryPathology Quality Assurance
Description

Independent external quality assurance service providing unbiased feedback on scanner artifacts, color calibration, image quality, and diagnostic accuracy of pathology reports, delivered through the network of expert pathologists.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Diagnexia and Artera partnership brings the first AI multimodal risk stratification tool for localised prostate cancer to the UK. The partnership provides rapid, reliable AI-powered insights to clinicians and patients, combining Diagnexia's digital pathology platform with Artera's AI technology.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Diagnexia is a supplier on The Countess of Chester Hospital National Framework Agreement for Teleradiology, Telepathology and Telemedicine Services, enabling any NHS hospital to access Diagnexia services through this framework.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

NHS hospitals including Bedfordshire Hospitals NHS Foundation Trust, East Sussex Healthcare NHS Trust, and Derriford Hospital access Diagnexia services for backlog management, primary reporting, and specialist consultations.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Innovation UK funded iCAIRD programme involving digital pathology deployment. Dr Gareth Bryson, Consultant Pathologist at Diagnexia, is Honorary Senior Lecturer at University of St Andrews contributing to this programme.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Diagnexia

Digital Pathology Servicesdiagnexia.com

Diagnexia is a cloud-based digital pathology services company that connects hospital laboratories to a global network of GMC-registered subspecialty pathologists for primary diagnostic reporting, secondary consultations, scanning, and clinical-trial support, primarily serving NHS hospitals via a national framework agreement and select international institutions.

What Diagnexia does

Diagnexia is a UK-headquartered digital pathology services company operating a cloud-based platform that connects hospital laboratories to a global network of GMC-registered subspecialty pathologists for primary diagnostic reporting (advertised 3–5 day turnaround, with live wait times showing 1.5 days) and secondary consultations (7–10 day turnaround, 4 days live). The company was founded in 2021, with corporate headquarters in Dublin, Ireland and UK operations centred on CQC-registered accessioning facilities in Exeter (digital accessioning) and Oxford (histology and digital accessioning, UKAS ISO 15189:2022 accredited as of November 2025); additional accessioning centres operate in Naperville, Illinois (US) and Toronto, Ontario (Canada), with primary reporting currently available in the UK and Canada.

The core product is the Diagnexia Hub cloud portal, which handles case onboarding, monitoring, and management with integrated synoptic reporting templates that export into customer laboratory information systems (LIS). Supporting offerings include Scanning Services (client-supplied or Diagnexia-operated scanners at its accessioning centres), Analytix (a sub-brand targeting translational research and clinical trials), External Quality Assurance services aligned to NEQAS schemes, and educational programmes including the Diagnexia Dialogues podcast, an annual Histopathology Symposium, and a Computational Pathology Fundamentals course. The platform also integrates an AI multimodal prostate cancer risk stratification tool through a strategic partnership with Artera.

Diagnexia monetizes per-case pathology reporting fees on a quote-based, multi-year subscription model. Its go-to-market is enterprise sales to NHS hospitals, with distribution via The Countess of Chester Hospital National Framework Agreement for Telepathology, Telepathology and Telemedicine Services — a procurement vehicle that gives any NHS hospital in England transparent, pre-cleared access — supplemented by direct contracts with named NHS Trusts (Derriford Hospital, Bedfordshire Hospitals NHS Foundation Trust, East Sussex Healthcare NHS Trust) and international healthcare institutions in Canada and beyond. The company reports no disclosed revenue or institutional venture funding; the only documented capital inflow is an approximately £50,000 grant from Heart of the South West LEP (via the European Regional Development Fund) in August 2023 to purchase a digital pathology scanner.

Diagnexia firmographics

Firmographics
Name
Diagnexia
Legal name
Diagnexia UK Limited
Website
https://diagnexia.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
Diagnexia is a cloud-based digital pathology services company that connects hospital laboratories to a global network of GMC-registered subspecialty pathologists for primary diagnostic reporting, secondary consultations, scanning, and clinical-trial support, primarily serving NHS hospitals via a national framework agreement and select international institutions.
Ownership category
akta.pro rank

Diagnexia industry classification

Industry
Product category
Digital Pathology Services
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLACAMAB
Anatomic Pathology LIS & Digital Pathology Workflow
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLALALAG
Diagnostic/Lab & Imaging Referral Marketplaces
Healthcare & Life Sciences/Telehealth Platforms/Telehealth Marketplace & Referral Platforms
SECONDARYHLACAMAJ
Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAFAMAA
Anatomic Pathology (Histopathology & Cytopathology)

Keywords

  • Digital pathology services
  • Telepathology reporting
  • Clinical trial pathology
  • Pathology quality assurance
  • Subspecialty pathologist network

Where Diagnexia is headquartered

Location

Headquarters

HQ city
Exeter
HQ country
United Kingdom
HQ region
Europe

Offices5 records

Markets served

Diagnexia business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Digital Pathology Reporting Services: Provides primary diagnostic reporting (3-5 day turnaround) and secondary consultation services (7-10 day turnaround) for NHS hospitals and healthcare institutions. Revenue generated through service fees for pathology reporting, with transparent pricing for NHS Framework access.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractPrimary Diagnostic Reporting

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Diagnexia product offering

Product offering

Core offering

Diagnexia operates a cloud-based digital pathology platform that connects laboratories to a global network of GMC-registered subspecialty pathologists, delivering primary diagnostic reporting and secondary consultation reports for NHS hospitals and healthcare institutions. The company runs UKAS-accredited histology and digital accessioning centres in the UK and provides scanning services, clinical trial pathology support, and external quality assurance services.

Product overview

Diagnexia is a cloud-based digital pathology platform that functions as a 'global digital pathology department,' connecting laboratories worldwide to an international network of subspecialty pathologists. The core product is the Diagnexia Hub platform, which enables primary diagnostic reporting (3-5 day turnaround) and secondary consultation services (7-10 day turnaround). Supporting services include Scanning Services (with two workflow options: client scanner or Diagnexia scanning), Analytix for clinical trials, and External Quality Assurance services. The company also provides educational offerings including the Diagnexia Dialogues podcast and annual Histopathology Symposium events.

Differentiator

Problem solved

Functional benefit

Products and services

  • Digital Pathology Reporting Services Cloud-based delivery of primary diagnostic reports (3-5 day turnaround) and secondary consultation reports (7-10 day turnaround) from a global network of subspecialty pathologists, primarily for NHS hospitals and international healthcare institutions.
  • Scanning Services Digital pathology slide scanning services with two workflow options: clients use their own scanners or mail slides to Diagnexia's UK or US accessioning centres for digitization and end-to-end specimen tracking.
  • Analytix (Clinical Trials Pathology) Digital pathology services designed for translational research and clinical trials, supporting biopharma sponsors with pathology analysis for drug development studies.
  • External Quality Assurance (EQA) Services Independent external quality assurance service providing unbiased feedback on scanner artifacts, color calibration, image quality, and diagnostic accuracy of pathology reports, delivered through the network of expert pathologists.

Quantifiable outcome

  • 3-5 day turnaround for primary diagnostic reports
  • +3 more outcomes

Companies that use Diagnexia

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles3 records

Diagnexia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Diagnexia partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • ArteracoreStrategic or Co-development PartnerDiagnexia and Artera partnership brings the first AI multimodal risk stratification tool for localised prostate cancer to the UK. The partnership provides rapid, reliable AI-powered insights to clinicians and patients, combining Diagnexia's digital pathology platform with Artera's AI technology.
  • Countess of Chester Hospital NHS Foundation TrustcoreChannel Partner/ Reseller/ DistributorDiagnexia is a supplier on The Countess of Chester Hospital National Framework Agreement for Teleradiology, Telepathology and Telemedicine Services, enabling any NHS hospital to access Diagnexia services through this framework.
  • NHS Trusts (General)coreChannel Partner/ Reseller/ DistributorNHS hospitals including Bedfordshire Hospitals NHS Foundation Trust, East Sussex Healthcare NHS Trust, and Derriford Hospital access Diagnexia services for backlog management, primary reporting, and specialist consultations.
  • iCAIRD ProgrammeminorStrategic or Co-development PartnerInnovation UK funded iCAIRD programme involving digital pathology deployment. Dr Gareth Bryson, Consultant Pathologist at Diagnexia, is Honorary Senior Lecturer at University of St Andrews contributing to this programme.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Diagnexia competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Diagnexia social profiles

Digital presence

Diagnexia compliance and trust

Trust signal

Compliance4 records

Diagnexia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Diagnexia leadership team

Management profile

Number of profiles

Profiles2 records

Diagnexia funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Diagnexia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diagnexia

What does Diagnexia do?

Diagnexia operates a cloud-based digital pathology platform that connects laboratories to a global network of GMC-registered subspecialty pathologists, delivering primary diagnostic reporting and secondary consultation reports for NHS hospitals and healthcare institutions. The company runs UKAS-accredited histology and digital accessioning centres in the UK and provides scanning services, clinical trial pathology support, and external quality assurance services.

Is Diagnexia a public or private company?

Diagnexia is a private company. It is classified as unknown and is currently operating.

When was Diagnexia founded?

Diagnexia was founded in 2021. It employs 51 to 100 people.

Where is Diagnexia based?

Diagnexia is headquartered in Exeter, United Kingdom, in the Europe region.

How does Diagnexia make money?

One revenue line is on record: digital Pathology Reporting Services.

Does Diagnexia have an API?

No public API is recorded for Diagnexia.

What industry is Diagnexia in?

Diagnexia's product category is Digital Pathology Services. Its primary akta.pro industry code is HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow, with a secondary code of HLALALAG, Diagnostic/Lab & Imaging Referral Marketplaces. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooUK pathology provider Diagnexia chooses Sectra to speed up pathology reporting for the NHSSectra signed an agreement with UK pathology provider Diagnexia to deliver its Sectra Image Exchange Portal for advanced pathology workflows. The service, already used by over 500 institutions, will support NHS telepathology networks and cover up to 100,000 cases in the first year.PR NewswireUK pathology provider Diagnexia chooses Sectra to speed up pathology reporting for the NHSSectra signed an agreement with UK pathology provider Diagnexia to deliver its Sectra Image Exchange Portal for advanced share and collaborate workflows. The service covers up to 100,000 cases in the first year and integrates with NHS labs' existing LIS and PACS. The contract renews annually and supports national telepathology networks.DiagnexiaDiagnexia Launches Enterprise Platform for Digital Pathology, Revolutionizing US Laboratory CoverageDiagnexia launched an enterprise-grade digital pathology platform on January 28, 2025, designed to connect US laboratories with a network of board-certied pathologists. The platform aims to address rising locum costs and coverage gaps by offering same-day access to specialists through HIPAA-compliant cloud infrastructure and automated case routing.InsidermediaDiagnostics firm backed by funding boostDiagnostics firm Diagnexia has received a £49,780 grant from the Heart of the South West Local Enterprise Partnership to purchase a new digital pathology scanner. This investment supports the company's rapid expansion, which includes creating 35 new jobs and increasing capacity to handle a 450% growth in demand since late 2022.Business LiveHealth tech firm Diagnexia secures £50k for new kit and jobsHealth tech firm Diagnexia has secured £50,000 in funding from the Heart of the South West LEP to purchase a new digital pathology scanner and create five additional jobs. The investment supports the company's rapid expansion, which includes creating 30 previous roles and a 450% surge in service demand since December. This grant is drawn from the European Regional Development Fund and aims to reduce diagnosis delays through enhanced laboratory capabilities.BdailyExeter company receives funding boost to improve access to specialist servicesDiagnexia has received £49,780 in funding from the Heart of the South West Local Enterprise Partnership to purchase a new digital pathology scanner. This investment supports the company's rapid expansion, which includes creating 30 jobs and a 450% growth in demand since late 2022, while aiming to reduce diagnostic turnaround times for healthcare organizations.